Creative Touch Permanent Makeup and Aesthetics

Beta-hydroxybutyrate (BHB) is synthesised in hepatic mitochondria from acetyl-CoA derived from fatty acid β-oxidation, under conditions where oxaloacetate availability is insufficient to channel acetyl-CoA through the TCA cycle – the defining metabolic state of carbohydrate restriction. Circulating BHB rises from near-baseline concentrations (0.1–0.2mM fasting) to 0.5–1.0mM on a low-carbohydrate diet, and to 1.5–6mM in nutritional ketosis on a ketogenic diet. At these physiological ranges, BHB is not simply a fuel alternative – it has been shown through separate mechanistic pathways to modify gene expression, suppress inflammatory cascades, and reduce oxidative damage in ways that are consequential for skin biology. The significance of distinguishing BHB from the broader concept of a ketogenic diet is that the mechanism is attributable to the molecule, not the dietary pattern, and the molecular biology is therefore interpretable independently of the dietary context debate.

BHB as an HDAC Inhibitor

The landmark 2013 study published in Science (Shimazu et al.) identified BHB as an endogenous and specific inhibitor of class I and class IIa histone deacetylases (HDAC1, HDAC2, HDAC3), with inhibitory activity demonstrable at physiological concentrations achievable through fasting or carbohydrate restriction. ^[4] HDACs normally remove acetyl groups from histone lysine residues, compacting chromatin and suppressing gene transcription. HDAC inhibition by BHB increases histone acetylation at target promoters, opening chromatin and upregulating the expression of genes associated with oxidative stress resistance – most notably FOXO3a and MT2 (metallothionein 2).

FOXO3a is a transcription factor in the forkhead family that regulates a programme of cellular stress resistance: it upregulates superoxide dismutase (MnSOD), catalase, and other antioxidant enzymes, promotes DNA repair gene expression, and attenuates the NF-κB inflammatory programme. ^[2] In skin biology, FOXO3a activity is relevant to keratinocyte and fibroblast longevity, UV-damage resistance, and the suppression of the senescence-associated secretory phenotype (SASP) – the inflammatory output of senescent cells that drives chronic low-grade dermal inflammation. ^[5] The HDAC inhibitor literature in dermatology has separately demonstrated that HDAC inhibition accelerates wound closure, promotes a pro-regenerative macrophage phenotype, and suppresses MMP and cytokine expression – effects mediated by chromatin remodelling at the same class I HDAC targets that BHB inhibits. ^[3]

BHB-mediated HDAC inhibition also induces a distinct epigenetic modification: lysine β-hydroxybutyrylation (Kbhb), in which BHB itself is transferred onto histone lysine residues as a novel acylation mark. This modification is detectable across the genome and is associated with active transcription of metabolic and stress-response genes – a form of direct metabolic-to-epigenetic coupling that goes beyond classical HDAC inhibition. ^[5]

NLRP3 Inflammasome Inhibition

BHB directly inhibits the NLRP3 inflammasome – the intracellular multiprotein complex responsible for processing and secreting IL-1β and IL-18, two of the most potent drivers of skin and systemic inflammation. The mechanism operates through prevention of potassium (K⁺) efflux from macrophages, and through inhibition of ASC oligomerisation and speck formation – two events required for NLRP3 assembly and activation. Critically, this inhibitory effect is independent of BHB’s roles as a fuel substrate, HDAC inhibitor, or classical starvation-signalling pathways ( AMPK, ROS, autophagy), establishing it as a direct, structurally specific anti-inflammatory signal. ^[6]

BHB-mediated NLRP3 inhibition also reduces NF-κB phosphorylation, suppressing the transcriptional programme upstream of NLRP3 activation in addition to blocking the inflammasome complex itself. ^[1] The NLRP3 inflammasome is a relevant target in skin biology: it is constitutively activated in several inflammatory skin conditions including acne vulgaris (where P. acnes lipopolysaccharides are a classic NLRP3 activator), rosacea, psoriasis, and atopic dermatitis. Elevated IL-1β downstream of NLRP3 drives both the acute pustular inflammatory response in acne and the chronic dermal inflammatory milieu that impairs barrier recovery. BHB’s mechanism therefore intersects directly with the inflammatory pathways most relevant to common aesthetic skin presentations.

The connection to the Obesity entity is also mechanistically direct: the chronic low-grade inflammatory state of obesity is partly driven by sustained adipose macrophage NLRP3 activation and elevated IL-1β and IL-18 output. BHB-mediated NLRP3 inhibition during ketogenic or low-carbohydrate dietary intervention represents a plausible mechanistic contribution to the anti-inflammatory effects observed clinically with these dietary approaches – distinct from and additive to the insulin sensitivity improvements described in the Low-Carbohydrate Diet entity.

Nutritional Ketosis

Nutritional ketosis is the physiological state in which circulating BHB reaches 0.5mM or above, achieved through sustained very low-carbohydrate intake (typically below 50g/day), prolonged fasting (14+ hours depending on individual metabolic rate), or high-intensity aerobic exercise. It is not pathological ketoacidosis – the latter requires circulating BHB concentrations above 15–25mM, which do not occur in the presence of functioning insulin secretion. The skin relevance of nutritional ketosis is primarily the relevance of BHB itself: the signalling effects described above are concentration-dependent, and the NLRP3 and HDAC inhibition evidence is grounded in concentrations achievable within the nutritional ketosis range. Nutritional ketosis is therefore the dietary condition that reliably produces the BHB concentrations at which these mechanisms are active, rather than a mechanism in itself.

Calibrating the Evidence

The aesthetics-relevant evidence for BHB is mechanistically compelling at the molecular level but direct clinical evidence in skin outcomes specifically remains limited. The primary evidence is: (1) mechanism-level – the Science 2013 HDAC paper, the Nature Medicine 2015 NLRP3 paper, and subsequent confirmatory studies are high-quality primary research; (2) pathway-level – FOXO3a activity, NLRP3 suppression, NF-κB attenuation, and MMP reduction are all independently established as relevant to skin ageing and inflammatory skin conditions; (3) clinical gap – there are no large randomised controlled trials demonstrating BHB-mediated skin outcome improvements specifically. The honest framing is that BHB has well-characterised mechanisms with clear theoretical relevance to skin biology, that the pathway evidence is strong, and that the clinical translation in dermatological outcomes is a legitimate emerging area rather than an established evidence base. It differentiates from marketing claims about ketogenic diets and skin precisely because the mechanism is identifiable and specific – not a general health halo effect, but an attributable molecular signal.